

**Title:** IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages.

**Authors:** Fatema Al-Rashed<sup>1\*</sup>, Halemah AlSaeed<sup>1</sup>, Nourah Almansour<sup>1</sup>, Fahd Al-Mulla<sup>2</sup>, Yusuf A. Hannun<sup>3</sup>, and Rasheed Ahmad<sup>1</sup>

**Affiliation:** <sup>1</sup> Immunology and Microbiology Department, Dasman Diabetes Institute, Al-Soor Street, Dasman, Kuwait, PO BOX 1180, Dasman, 15462, State of Kuwait, <sup>2</sup> Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait, Kuwait. <sup>3</sup> Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA

**Running title:** gp130 Trans-Signaling in Cholesterol-Transport

**\*Correspondence:** Fatema Al-Rashed Ph.D., Scientist II, Microbiology & Immunology Department, Dasman Diabetes Institute, Al-Soor Street, Kuwait, P.O. Box 1180 Dasman, 15462 Kuwait. Phone: 965 2224 2999 Ext. 4311; Fax: 965 2249 2406; E-mail: [fatema.alrashed@dasmaninstitute.org](mailto:fatema.alrashed@dasmaninstitute.org)

## 1 Abstract

2 **Background:** Atherosclerosis epitomizes a multifaceted cardiovascular disorder, predominantly  
3 characterized by the accumulation of cholesterol-laden plaques within arterial walls. Despite substantial  
4 research, the precise mechanisms governing the formation of these cholesterol-rich plaques remain  
5 partially elucidated. This study delves into the complex interplay of interleukin-6 (IL-6) receptors,  
6 shedding light on their pivotal role in orchestrating cholesterol homeostasis in human macrophages.

7 **Methods:** This investigation evaluated the correlation between interleukin-6 (IL-6), its receptors  
8 (IL6R/CD126), and glycoprotein 130 (gp130), alongside established atherosclerosis biomarkers. The  
9 cohort comprised 142 subjects, balanced between lean and obese individuals (71 each). Subsequent  
10 analyses utilized THP-1-derived macrophages to discern the biochemical repercussions of inhibiting IL-6  
11 receptors on cellular mechanisms.

12 **Results:** Data indicates a significant upsurge in IL-6 secretion correlating with atherosclerotic  
13 manifestations in the obese subset, accompanied by a concomitant diminution in IL-6 receptors  
14 IL6R/CD126 and gp130 on circulating monocytes within this group. Pharmacological obstruction of the  
15 gp130 receptor in macrophages provoked pronounced alterations in lipid metabolism, notably impacting  
16 cholesterol management. These alterations were evidenced by an escalated expression of the LDLR gene,  
17 responsible for cholesterol uptake, and a surge in de novo cholesterol synthesis, marked by the  
18 upregulation of SREBF2 and its downstream effector, mevalonate kinase (MVK). Concurrently, an  
19 increase in HMG-CoA reductase protein levels was observed. Intriguingly, a rise in intracellular  
20 cholesterol production coupled with a reduction in ABCA1 levels was noted, suggesting a potential  
21 impediment in cholesterol efflux in cells deficient in gp130. This hypothesis was further substantiated by  
22 Filipin III staining, which indicated cholesterol retention in cells subjected to gp130 inhibition. Clinical  
23 implications of these discoveries were corroborated through experiments on PBMCs from lean  
24 participants, where the gp130 inhibitor curtailed cholesterol efflux to levels comparable to those in  
25 untreated cells.

26 **Conclusion:** Collectively, our research underscores the instrumental role of gp130 in the reverse  
27 cholesterol transport pathway of macrophages. These insights pave the way for novel therapeutic  
28 strategies targeting atherosclerosis and its associated cardiovascular complications, spotlighting gp130 as  
29 a potential focal point for intervention.

30

## 31 Introduction

32 Atherosclerosis is a major cause of morbidity and death in developed countries(1). While chronic  
33 systemic inflammation is widely acknowledged across all stages of atherosclerosis, it is universally  
34 understood that this disorder primarily stems from lipid irregularities, with evidence from the buildup of  
35 oxidized low-density lipoproteins (oxLDL) in macrophages within the arterial walls (2). Current insights  
36 suggest that during the development of the atherosclerotic lesions, plasma circulatory monocytes migrate  
37 into the space beneath the endothelium. Here, they evolve into macrophages, ingesting altered  
38 lipoproteins, and eventually become foam cells (3). This process is believed to be instigated via cell  
39 scavenger receptors like SR-A and CD36 (4) or through the incorporation of cholesterol-bearing  
40 lipoprotein particles via the low-density lipoprotein receptor (LDLR) (5), which promotes the  
41 accumulation of lipids within their cellular structures and leads to the formation of foam cells. Another  
42 route to cholesterol-laden macrophages arises from the engulfment of apoptotic cells through  
43 efferocytosis (6). All in all, a substantial influx of cholesterol could potentially be harmful if the recycling

44 of cholesterol within macrophages is disrupted (7, 8). It is interesting to point out that atherosclerosis is  
45 typically seen alongside other metabolic syndromes such as diabetes mellitus (DM), dyslipidemia and  
46 hypertension. Such observation strongly supports the vital impact of systemic inflammatory stimuli. Thus,  
47 a deeper understanding of the interaction between ox-LDL and inflammatory mediators involved in foam  
48 cell formation is critical to effectively prevent plaque rupture and the subsequent clinical life-threatening  
49 complications of atherosclerosis.

50 Interleukin-6 (IL-6) stands out as a notable cytokine within atherosclerotic tissue, with a substantial  
51 production originating from macrophages loaded with free cholesterol in advanced lesions (9). IL-6  
52 receptors, including the primary IL-6 receptor (IL-6R) and the shared signal transducing subunit  
53 glycoprotein 130 (gp130), form a crucial duo in orchestrating cellular responses to interleukin-6 (IL-  
54 6)(10). The IL-6/gp130 complex activates the JAK/STAT3 pathway, triggering a cascade of events that  
55 regulate immune and inflammatory responses. It is noteworthy that IL-6 has been established as an  
56 independent risk factor for early coronary artery disease (11). Moreover, elevated levels of IL-6 are linked  
57 to an increased likelihood of myocardial infarction in healthy men (12). However, the precise role of IL-6  
58 remains uncertain especially under different feeding habits, whether it acts as a causative factor, a  
59 consequence, or simply a marker of atherosclerosis. Indeed, experiments conducted on genetically  
60 modified mouse models predisposed to atherosclerosis reveal contradictory functions of IL-6 (13, 14). For  
61 instance, treating mice with recombinant mouse IL-6 resulted in larger lesions in both C57BL/6 and  
62 apoE-deficient mice fed a high fat/cholate diet (15). On the other hand, IL6-deficient mice developed  
63 larger fatty streak lesions compared to control mice when subjected to an atherogenic diet for 15 weeks  
64 (13).

65 To this end, the interplay between IL-6 receptors and secretion, especially in the cholesterol-rich  
66 inflammatory environment emblematic of atherosclerosis, is still under exploration. This study aims to  
67 discern the expression and correlation of IL-6 receptors (IL-6R/gp130) in human PBMCs isolated from  
68 both lean and obese subjects. Our findings indicate that in an obesity context, a spike in IL-6 secretion in  
69 media corresponds to an augmented cardiovascular risk, evident from the upregulation of total  
70 cholesterol. Conversely, the surface expressions of IL-6 receptors (IL6R/CD126) and gp130 were  
71 significantly diminished in obese participants. Delving deeper mechanistically using THP-1 transformed  
72 macrophages, we observed that the absence of the IL-6 receptor gp130 influenced macrophage cholesterol  
73 transport dynamics, amplifying cholesterol influx and curtailing cholesterol efflux, thus influencing  
74 macrophage cholesterol equilibrium favoring macrophage foaming.

75

## 76 **Materials and methods:**

### 77 *Study Design and Participant Recruitment:*

78 This investigation enlisted 142 individuals from a previously reported cohort (16, 17), all of whom were  
79 robust adults devoid of medical conditions, ensuring optimal physical health without any disabilities  
80 impeding movement. The study protocol entailed two distinct visits per participant. The initial encounter  
81 was dedicated to briefing the participants about the study specifics, potential risks, and subsequent  
82 procedures. Post briefing, participants who consented to partake in the study signed an informed consent  
83 form and underwent a comprehensive health screening.

84

### 85 *Data Collection and Assessment Procedures:*

86 Subsequent to the initial visit, participants were equipped with wearable accelerometers to monitor  
87 physical activity over a span of seven days. The follow-up visit encompassed comprehensive  
88 anthropometric and biomedical evaluations. The study adhered to a standardized protocol for all  
89 anthropometric measurements, employing consistent equipment to ensure uniformity. Height was  
90 accurately gauged using a portable stadiometer, with a precision of up to 1.0 cm, while weight  
91 measurements were ascertained to the nearest 0.2 kg using a standard physician's beam scale (Detecto).  
92 The Body Mass Index (BMI) was computed using the standard formula: weight in kilograms divided by  
93 the square of height in meters ( $\text{kg}/\text{m}^2$ ).

94

#### 95 *Biomedical Evaluations and Ethical Considerations:*

96 Post anthropometric assessment, participants proceeded to the phlebotomy unit for blood sample  
97 collection. Detailed physical and biochemical profiles of the participants, categorized by BMI, are  
98 delineated in Supplementary Table 1. The study was meticulously conducted in strict adherence to the  
99 ethical guidelines delineated in the Declaration of Helsinki. Ethical approval for the study was secured  
100 from the Kuwait Ministry of Health Ethical Board (Approval ID#: 1806/2021) and the Ethical Review  
101 Committee (ERC) of the Dasman Diabetes Institute, Kuwait (Approval ID#: RA MoH-2022-002),  
102 ensuring all participants provided written informed consent prior to their inclusion in the study.

103

#### 104 *Isolation of human peripheral blood mononuclear cells (PBMC):*

105 Peripheral blood mononuclear cells (PBMCs) were meticulously extracted from EDTA-treated vacutainer  
106 tubes collected from all study participants. The cells were isolated employing the Histo-Paque density  
107 gradient method in conjunction with Sepmate Tubes (StemCell Technologies, Vancouver, CN,  
108 Canada)(18). For the derivation of monocytic cells, the isolated PBMCs were plated in 6-well or 24-well  
109 plates (Costar, Corning Incorporated, Corning, NY, USA) at a density of  $3 \times 10^6$  cells per well.

110

#### 111 *Monocytic Cell Cultivation Conditions:*

112 The plated cells were cultured in a starvation medium consisting of RPMI-1640 culture medium (Gibco,  
113 Life Technologies, Grand Island, NY, USA), enriched with 2 mM glutamine (Gibco), 1 mM sodium  
114 pyruvate, 10 mM HEPES, 100  $\mu\text{g}/\text{mL}$  Normocin, and 50 U/ml penicillin combined with 50  $\mu\text{g}/\text{mL}$   
115 streptomycin (P/S; Gibco). The incubation of the cells was conducted at a controlled temperature of  $37^\circ\text{C}$ ,  
116 in a humidified atmosphere containing 5%  $\text{CO}_2$ . After a period of 3 hours, non-adherent cells were gently  
117 removed to ensure the purity of the adherent monocytes. Subsequently, the adherent monocytes were  
118 rinsed with serum-free culture medium. The final cultivation phase involved a 24-hour incubation in  
119 RPMI supplemented with 2% fetal bovine serum, facilitating optimal cell growth and differentiation  
120 under these meticulously controlled conditions.

121

#### 122 *Measurement of blood metabolic markers:*

123 The protocol for assessing blood metabolic markers was rigorously followed as delineated in prior  
124 research (19). Prior to the collection of blood samples for plasma isolation, essential physiological  
125 parameters, including blood pressure and heart rate, were accurately measured for each participant.

126

127 *Plasma Isolation and Biochemical Analysis:*

128 Post-collection, isolated plasma served as the primary medium for the quantitative analysis of various  
129 metabolic indicators. This included the measurement of triglyceride levels, total cholesterol, high-density  
130 lipoprotein (HDL)-cholesterol, and fasting glucose concentrations. To ensure the reliability and accuracy  
131 of the metabolic marker assessments, quality control sera were systematically employed throughout the  
132 testing procedures. This meticulous approach underscored the commitment to precision and the integrity  
133 of the data obtained from these critical biochemical measurements.

134

135 *Enzyme-Linked Immunosorbent Assay (ELISA) for Biomarker Detection:*

136 For the precise quantification of matrix metalloproteinase 9 (MMP9) and vascular endothelial growth  
137 factor (VEGF), the study employed commercially procured enzyme-linked immunosorbent assay  
138 (ELISA) kits (R&D Systems, Minneapolis, MN, USA). The assay procedures were meticulously executed  
139 in strict accordance with the manufacturer-provided protocols and guidelines established by previously  
140 published methodologies. This stringent adherence ensured the reliability and accuracy of the biomarker  
141 detection, fostering robust and replicable results within the study's framework.

142

143 *Cell Culture and Differentiation*

144 *Cultivation and Differentiation of Human Monocytic THP-1 Cells:*

145 Human monocytic THP-1 cells, acquired from the American Type Culture Collection (ATCC), were  
146 cultured in RPMI-1640 culture medium (Gibco, Life Technologies, Grand Island, USA). The culture  
147 medium was fortified with 10% fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM  
148 HEPES, 100 µg/ml Normocin, and 50 U/ml penicillin, along with 50 µg/ml streptomycin (P/S; Gibco,  
149 Invitrogen, Grand Island, NY, USA). The cells were maintained under precise conditions at 37°C, in a  
150 humidified atmosphere supplemented with 5% CO<sub>2</sub>. For experimental purposes, the monocytic cells were  
151 seeded into 12-well plates (Costar, Corning Incorporated, Corning, NY, USA) at a density of 1×10<sup>6</sup> cells  
152 per well, unless specified otherwise.

153

154 *Macrophage Differentiation and Stimulation Protocol:*

155 Prior to stimulation, the monocytic cells underwent differentiation into macrophages using 10 ng/ml  
156 phorbol-12-myristate-13-acetate (PMA) over a period of three days. This was followed by a resting phase  
157 of an additional three days in serum-PMA-free RPMI media, ensuring the cells were fully primed for  
158 subsequent treatments. In the subsequent stimulation studies, differentiated macrophages were initially  
159 pre-treated with 10 ng/ml of SC144 (to inhibit the gp130 receptor), recombinant human IL-6 (hrIL-6), or  
160 a vehicle control for one hour. Post pre-treatment, the cells were stimulated with Human High Oxidized  
161 Low-Density Lipoprotein (oxLDL) (KB KALAN Biomedical; Cat no: 770252-4) for a duration of 24  
162 hours, setting the stage for the exploration of various cellular responses and interactions under these  
163 defined conditions.

164

165 *Real-Time Quantitative RT-PCR Process:*

166 The extraction of total RNA was conducted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA),  
167 strictly adhering to the manufacturer's specified protocol. Following extraction, cDNA synthesis was  
168 performed utilizing 1 µg of total RNA with the aid of a high-capacity cDNA reverse transcription kit  
169 (Applied Biosystems, Foster City, CA, USA). The quantification of gene expression was carried out using  
170 the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), coupled with the  
171 TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City).

172

173 *Amplification and Data Normalization:*

174 For each reaction, 50 ng of cDNA was amplified using Inventoried TaqMan Gene Expression Assay  
175 products. The threshold cycle (Ct) values obtained were normalized against the housekeeping gene  
176 GAPDH to ensure accuracy in the relative quantification of the target mRNA. The relative quantities of  
177 mRNA, in comparison to control samples, were computed employing the  $\Delta\Delta C_t$ -method, with the  
178 expression levels presented as fold-change relative to the mean expression of the control gene. The  
179 baseline expression level for the control treatment was set at 1. Data are represented as mean  $\pm$  SEM. The  
180 threshold for statistical significance was established at  $p < 0.05$ . For a comprehensive overview of the  
181 primers utilized in the study, refer to Supplementary Table 2, where the primer list is extensively detailed.

182

183 *Western Blotting Procedure:*

184 For Western blot analysis, cells were first collected and then incubated with lysis buffer (comprising Tris  
185 62.5 mM at pH 7.5, 1% Triton X-100, and 10% glycerol) for a duration of 30 minutes. Post-incubation,  
186 the cell lysates underwent centrifugation at 14,000x g for 10 minutes, facilitating the separation and  
187 subsequent collection of the supernatants. The protein concentration within these lysates was  
188 quantitatively assessed using the Quickstart Bradford Dye Reagent, 1x Protein Assay kit (Bio-Rad  
189 Laboratories, Inc, CA).

190

191 *Sample Preparation and Gel Electrophoresis:*

192 Protein samples (50 µg in 20 µl) were prepared by mixing with sample loading buffer and then heated for  
193 5 minutes at 95°C. A quantity of 12.5 µg from these prepared samples was loaded and subjected to  
194 electrophoretic separation on 12% polyacrylamide gels using SDS-PAGE. Subsequently, the separated  
195 cellular proteins were transferred onto Immuno-Blot PVDF membranes (Bio-Rad Laboratories, USA)  
196 through electroblotting.

197

198

199 *Membrane Processing and Visualization:*

200 The membranes were initially blocked using 5% non-fat milk in PBS for one hour to prevent non-specific  
201 binding. This was followed by incubation with various primary antibodies (detailed in Supplementary  
202 Table 3). After primary antibody incubation, the membranes were washed four times with TBS and then  
203 incubated for 2 hours with species-specific HRP-conjugated secondary antibodies (Promega, Madison,



204 WI, USA). The immunoreactive bands were visualized through the use of the Amersham ECL plus  
205 Western Blotting Detection System (GE Health Care, Buckinghamshire, UK) and captured using the  
206 Molecular Imager ® ChemiDoc™ MP Imaging Systems (Bio-Rad Laboratories, Hercules, CA, USA),  
207 ensuring clear and precise documentation of the protein expression patterns.

208

#### 209 *Cholesterol Efflux Assay Implementation:*

210 The measurement of cholesterol efflux was rigorously performed in accordance with the protocol  
211 specified by the Cholesterol Efflux Assay Kit (Cell-based) (abcam; ab196985). This involved the  
212 incubation of either differentiated cells or isolated PBMCs with labeling and equilibrium mediums.  
213 Following this preparatory step, the cells underwent a treatment phase with cholesterol acceptors for a  
214 period of four hours, utilizing LDL/VLDL-depleted human serum as the specific cholesterol acceptor for  
215 the assay.

216

#### 217 *Fluorescence Quantification and Efflux Percentage Calculation:*

218 Post-treatment, the fluorescence emanating from the cell lysate was measured at the wavelengths of  
219 485/523 nm. This fluorescence measurement is critical as it reflects the extent of cholesterol that has been  
220 effluxed from the cells. To accurately quantify the percentage of cholesterol efflux, the following formula  
221 was applied:

$$222 \quad \% \text{ Cholesterol Efflux} = (\text{RFU of Supernatant}) / (\text{RFU of Cell Lysate} + \text{RFU of Supernatant}) \times 100$$

223

#### 224 *Flow Cytometry—Staining of Cell-Surface Markers*

225 To determine the expression of IL-6 receptors; IL-6Ra/ CD126 and gp130/CD130 in circulatory  
226 monocytes, flow cytometry analysis was conducted using the isolated PBMCs. The cells were first  
227 resuspended in FACS staining buffer (BD Biosciences) and subjected to a blocking phase with human  
228 IgG (Sigma; 20 µg) for 30 minutes on ice. Post-blocking, the cells underwent a washing step, followed by  
229 resuspension in 100 µL of FACS buffer.

#### 230 *Staining and Incubation Procedures:*

231 For the staining process, the cells were treated with mouse anti-human CD14-PE-Cy™7 (cat# 560919,  
232 BD Pharmingen™), mouse anti-human CD126- APC (cat# 562090, BD Pharmingen™), and mouse anti-  
233 human CD130- PE (cat# 555757, BD Pharmingen™). The stained cells were incubated on ice for a total  
234 of 30 minutes, with gentle mixing at 10-minute intervals to ensure uniform staining. This was followed by  
235 three washes with FACS buffer and a final fixation step, involving resuspension in 2% paraformaldehyde  
236 solution.

237

#### 238 *Intracellular Staining and FACS Analysis:*

239 For intracellular staining, cells were treated with fixation/permeabilization buffer (Cat# 00-5523-00,  
240 eBioscience, San Diego, CA, USA) for 20 minutes at 4°C, then washed and stained with intracellular  
241 inflammatory cytokine rat anti-human IL-6- PE (cat# 554545, BD Pharmingen™). Following staining,

242 the cells were washed again and resuspended in PBS supplemented with 2% FCS for subsequent FACS  
243 analysis (FACSCanto II; BD Bioscience, San Jose, USA). Data analysis was executed using BD  
244 FACSDiva™ Software 8 (BD Biosciences, San Jose, USA). To accurately set the thresholds for negative  
245 versus positive gates, non-stain cells and isotype-specific respective control antibodies were employed.

246

#### 247 *Oil-Red-O Lipid Staining Procedure:*

248 The visualization of lipid accumulation in treated cells was achieved through the application of Oil-Red-O  
249 lipid staining, a technique renowned for its specificity to lipids, primarily triglycerides and lipoproteins.

250

#### 251 *Preparation and Fixation of Cells:*

252 Initially, the treated cells were gently washed with PBS to remove any residual media or non-adherent  
253 cells. This was followed by a fixation process, where the cells were immersed in 10% formalin solution  
254 for a duration of 30 minutes, ensuring the preservation of cellular structures and lipid content.

255

#### 256 *Staining and Visualization Process:*

257 Post fixation, the cells were subjected to a series of washes with ddH<sub>2</sub>O to remove the fixative.  
258 Subsequently, the cells were prepared for staining by incubating them in 60% isopropanol for 5 minutes.  
259 This step enhances the permeability of the cell membrane, facilitating the effective penetration of the Oil  
260 Red O stain. The Oil Red O working solution, freshly prepared and reconstituted with water, was then  
261 added to the cells and allowed to incubate for 20 minutes. During this period, the lipid components within  
262 the cells selectively absorbed the stain. Following the incubation, the excess stain was carefully discarded,  
263 and the cells were thoroughly washed with ddH<sub>2</sub>O to remove any non-specifically bound stain. and were  
264 considered ready for visualization under the microscope.

265

#### 266 *Filipin cholesterol staining*

267 Treated cells were fixed using 4% paraformaldehyde, rinsed, and then incubated with Filipin complex (50  
268 µg/ml) for two hours at room temperature, protected from light. Post-staining, samples were washed and  
269 mounted for fluorescence microscopy. Imaging was performed using a UV filter set to specifically  
270 capture Filipin's fluorescence with excitation (355 nm) and emission (420 nm) through a standard UV  
271 filter block. Image acquisition was standardized to minimize photo-oxidation and fading.

#### 272 *BODIPY neutral lipid staining*

273 For the detection of neutral lipids, BODIPY 493/503 was used. After fixing with 4% paraformaldehyde,  
274 cells were stained with BODIPY 493/503 at a concentration of 2µM for 15 minutes at room temperature  
275 in the dark. Following staining, cells were washed and mounted for imaging. We used fluorescence  
276 microscopy with the appropriate filters to detect BODIPY's green fluorescence at excitation of (493nm)  
277 and emission of (503 nm), carefully calibrating the settings to prevent photobleaching.

#### 278 *Phalloidin f-actin staining*



279 Phalloidin stain (6.6  $\mu$ M) diluted with PBS used to incubate the cells for 20min at room temperature, then  
280 the cells are visualized under fluorescent microscopy.

281

282 *Confocal Microscopy Imaging Protocol:*

283 *Instrumentation and Configuration:*

284 Imaging was conducted using an inverted Zeiss LSM710 spectral confocal microscope (Carl Zeiss,  
285 Gottingen, Germany), paired with an EC Plan-Neofluar 40 $\times$ /1.30 oil DIC M27 objective lens. The  
286 samples underwent excitation utilizing a dual-laser system comprising a 543 nm HeNe laser and the 405  
287 nm line of an argon ion laser, ensuring optimal illumination for each specific fluorophore. Following  
288 excitation, the emission detection bandwidths were optimized and configured using the Zeiss Zen 2010  
289 control software. This careful calibration was crucial for accurately capturing the fluorescence emissions,  
290 thereby allowing for precise and detailed visualization of the cellular structures and components under  
291 study.

292

293 *Statistical Methodology and Data Presentation:*

294

295 The statistical analyses were executed using GraphPad Prism software (La Jolla, CA, USA). Data are  
296 presented as mean  $\pm$  standard error of the mean (SEM) unless specified otherwise.

297

298 *Normality Testing and Group Comparison Methods:*

299

300 Initial data examination included the Shapiro–Wilk test to confirm normal distribution. For comparative  
301 analyses, group means were contrasted using two-tailed tests for parametric data and Wilcoxon–Mann–  
302 Whitney U tests for non-parametric datasets, ensuring appropriate and robust statistical inference.  
303 Additionally, for assessments involving three groups, one-way ANOVA and exact Kruskal–Wallis tests  
304 were employed for parametric and non-parametric data respectively, catering to the dataset's distribution  
305 characteristics.

306

307

308 *Correlation Analysis and Significance Thresholds:*

309 Correlation strength and direction between two variables were quantified using Pearson's correlation  
310 coefficient "r" for parametric data, and Spearman's correlation coefficient for non-parametric datasets.  
311 The significance threshold was set at  $P < 0.05$ . The study further delineates levels of significance with  
312 notations: ns (non-significant), \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$ , in comparison to  
313 control, facilitating a nuanced understanding of the statistical findings in relation to the control group.

314

## 315 **Results**

316 *Obese individuals exhibit higher IL-6 plasma levels and reduced expression of IL-6 receptors on*  
317 *circulatory monocytes.*

318 To begin investigating the potential role of IL-6 receptors in modulating human macrophages'  
319 maintenance of cholesterol homeostasis, we first assessed the secretion of IL-6 cytokine in our cohort.

320 Similar to previous findings, the plasma secretion of IL-6 in our cohort was found to be significantly  
321 elevated in obese individuals compared to lean participants (**Figure 1A**). This observed elevation in IL-6  
322 secretion was also observed to be parallel with the increase in atherosclerosis indicators, including total  
323 cholesterol (**Figure 1B**), triglycerides (TG) (**Figure 1C**), and C-reactive protein (CRP) (**Figure 1D**),  
324 while also aligning with the reduction in high-density lipoprotein (HDL) levels (**Figure 1E**). Further  
325 correlation analysis showed a significant positive association of IL-6 plasma secretion with adverse  
326 atherosclerotic markers including total cholesterol, TG and CRP, whereas as expected a significant  
327 negative association with HDL (**Figure 1F-1I**).

328 However, further investigation on the expression and activity of IL6 receptor IL6R/CD126 through flow  
329 cytometry defined a different dynamic, as it was observed that lean participants presented a significantly  
330 higher representation of CD14<sup>+</sup>CD126<sup>+</sup> expression on their circulatory monocyte surface (**Figure 2A**).  
331 This expression was positively associated with elevated HDL levels in the plasma (**Figure 2B**) and  
332 negatively correlated with lower systolic and diastolic blood pressure in participants (**Figure 2F and 2G**).  
333 However, no significant association was found to other measured atherosclerotic markers including TG,  
334 total cholesterol and heart rate (HR) (**Figure 2C, 2D, and 2E**). We also did not observe any association  
335 between IL-6R surface expression and atherosclerotic inflammatory markers CRP, Matrix  
336 metalloproteinase 9 (MMP9) or Vascular endothelial growth factor (VEGF) (**Figure 2H-2J**).

337

338 Interestingly, when we measured the expression levels of the membrane glycoprotein 130 (gp130)  
339 transducing chain through flowcytometry analysis of CD130 surface marker, we encountered a higher  
340 abundance in all participants with a similar pattern of elevated CD126 expression observed in lean  
341 participants compared to those with obesity (**Figure 3A**). Unlike CD126, the elevated expression levels of  
342 gp130 were found to be significantly associated with further favorable lipid markers for atherosclerosis.  
343 Elevated gp130 expression was positively correlated with higher HDL (**Figure 3B**) and negatively  
344 associated with total cholesterol and TG (**Figure 3C and 3D**). The elevation of gp130 expression was  
345 also found to be associated with significantly reduced systolic and diastolic blood pressure with no impact  
346 on HR (**Figure 3E- 3G**). Most importantly, gp130 expression levels was significantly found to be  
347 associated with all measured atherosclerotic inflammatory markers (**Figure 3H -3J**), raising the  
348 possibility of a prominent role of gp130 in activating the downstream inflammatory signal for these  
349 observed markers.

350 Overall, these results indicate that elevated IL-6 secretion was associated with atherosclerotic indicators  
351 in obese individuals, while decrease in IL-6R and gp130 expression on circulatory monocytes was noted  
352 in the same cohort. Increased gp130 expression positively correlated with HDL and negatively correlated  
353 with total cholesterol, TG in lean individuals indicating a central function of IL-6R and gp130 in  
354 controlling pathology of atherosclerosis.

355

356 *Pharmaceutical inhibition of gp130 receptor induces lipid accumulation in macrophages.*

357 The role of the JAK/STAT3 pathway downstream of gp130 signaling is well documented to promote  
358 atherosclerosis development (20). To define the role of this observed decrease in gp130 in atherosclerosis  
359 at the molecular level, we treated macrophages derived from THP-1 cells with 10ng/ml of the gp130  
360 inhibitor SC144 in the presence and absence of oxLDL. The inhibition of the gp130 receptor had a  
361 significant impact on the level of intracellular lipid accumulation within the macrophages; this impact was  
362 further enhanced in the presence of oxLDL, showing positive cytoplasmic granularity and neutral lipid

363 accumulation measured through oil red O staining (**Figures 4A and 4B**). The influence of SC144 on lipid  
364 accumulation was further supported by the increase in PLIN2 gene expression (**Figure 4C**), which  
365 advocates the formation of lipid droplets under gp130 inhibition. Furthermore, we aimed to delve deeper  
366 into understanding the impact of gp130 inhibition on lipid accumulation by examining the expression of  
367 key genes recognized for their control over various facets of lipid metabolism. The inhibition of gp130  
368 significantly upregulated low-density lipoprotein receptor (LDLR) gene expression regardless of oxLDL  
369 supplementation (**Figure 4D**). Interestingly, no statistically significant alteration was observed in CD36  
370 gene expression (**Figure 4E**), reinforcing the specificity of the observed effects on cholesterol regulation.

371 Furthermore, our findings present a remarkable reduction in expression of Fatty Acid Binding Protein 4  
372 (FABP4), underscoring the inhibitor's capacity to modulate fatty acid shuttling across the cytoplasm.  
373 However, under the influence of oxLDL supplementation, this effect was nullified, giving rise to a  
374 pervasive elevation evident in both the vehicle and SC144 test groups (**Figure 4F**). Interestingly, an  
375 opposite observation was demonstrated with FABP5 as it showed a significant elevation in its expression  
376 under both oxLDL presence and absence (**Figure 4G**).

377 No Significant change in the gene expression of Acetyl-CoA Carboxylase Alpha (ACACA), which serves  
378 as the rate-limiting catalyst for long-chain fatty acid biosynthesis (**Figure 4H**). In contrast, similar to  
379 oxLDL treated group, a notable reduction was observed under SC144 treatment in comparison to their  
380 respective vehicle control regardless of oxLDL presence. This observation was found in the gene  
381 expression of Fatty Acid Synthase (FASN), a downstream component of ACACA (**Figure 4I**), as well as  
382 Diacylglycerol O-Acyltransferase (DGAT), a pivotal enzyme in the metabolic pathway essential for  
383 triacylglycerol production (**Figure 4J**). Furthermore, gp130 inhibition induced significant reduction in  $\beta$ -  
384 oxidation, since the expression of Acyl-CoA Dehydrogenase Long Chain (ACADL) and both Carnitine  
385 palmitoyl transferase 1/2 (CPT1A and CPT2) were reduced compared to controls regardless to oxLDL  
386 treatment as well (**Figure 4K to 4M**). Under gp130 inhibition, the observed profile includes macrophage  
387 foaming, elevated expression of cholesterol regulatory uptake receptors and fatty acid transportation, and  
388 reduced de novo lipogenesis, triglyceride production, and liberation. This suggests an association with  
389 increased lipid influx and utilization, reflecting the cell's effort to regulate its response and prevent further  
390 uptake and synthesis of fatty acids in the absence of the gp130 receptor. These findings potentially  
391 contribute to shifts in lipid metabolism and related pathways, primarily within the realm of cholesterol  
392 metabolism.

393

394 *Pharmaceutical inhibition of gp130 receptor modulates cholesterol homeostasis program in*  
395 *macrophages.*

396 In order to gain deeper insights into the role of the gp130 receptor in macrophage cholesterol  
397 homeostasis, we conducted a comprehensive investigation into the impact of the gp130 inhibitor SC144,  
398 both in the presence and absence of oxLDL, on a select subset of key genes involved in cholesterol  
399 homeostasis. Similar to our previous analysis, we employed quantitative polymerase chain reaction  
400 (qPCR) to assess the expression levels of these genes, allowing us to elucidate the molecular mechanisms  
401 underlying cholesterol regulation in macrophages. Our initial findings revealed that the inhibition of the  
402 gp130 receptor did not elicit a significant alteration in the expression of the Sterol Regulatory Element-  
403 Binding Transcription Factor 1 (SREBF1) gene when compared to the vehicle control. Interestingly,  
404 however, both vehicle-treated and SC144-treated macrophages exhibited a reduction in SREBF1  
405 expression upon oxLDL stimulation (**Figure 5A**). This observation suggests that oxLDL plays a pivotal  
406 role in modulating the expression of this gene, irrespective of gp130 inhibition. Remarkably, a

407 noteworthy trend was observed in the expression of SREBPF2 under conditions of gp130 inhibition,  
408 although this increase did not reach statistical significance. Of particular interest was the finding that  
409 following oxLDL stimulation, the expression of SREBF2 remained significantly elevated in the presence  
410 of gp130 inhibition whereas oxLDL-treated vehicle cells exhibited a significant drop in expression  
411 compared to non-stimulated vehicle cells (**Figure 5B**). This suggests that gp130 inhibition may contribute  
412 to the sustained upregulation of SREBF2 in response to oxLDL.

413 The impact of SREBF2 gene expression was further reflected downstream in the expression of  
414 Mevalonate Kinase (MVK). Notably, a similar trend of significant upregulation in cholesterol  
415 biosynthesis was observed under conditions of gp130 inhibition, regardless of oxLDL stimulation (**Figure**  
416 **5C**). These findings indicate a role for gp130 in regulating cholesterol biosynthesis, particularly through  
417 the modulation of SREBPF2 and its downstream targets. Additionally, we examined the expression of  
418 ATP Binding Cassette Subfamily A Member 1 (ABCA1) and G Member 1 (ABCG1), both of which play  
419 crucial roles in cholesterol efflux and are regulated by SREBP2. The inhibition of gp130 resulted in a  
420 remarkable suppression of ABCA1 gene expression, which was not rescued even under oxLDL  
421 stimulation (**Figure 5D**). Conversely, no significant difference was detected in ABCG1 gene expression  
422 under SC144 treatment compared to the vehicle control, with oxLDL stimulation leading to a reduction in  
423 gene expression regardless of gp130 inhibition (**Figure 5E**). These findings highlight the distinct  
424 regulatory roles of gp130 in controlling these efflux-related genes. To further verify this observation, we  
425 explored whether gp130 inhibition could affect the total protein levels of cholesterol efflux protein  
426 ABCA1 and the cholesterol *de novo* synthesis enzyme HMG-CoA. Treatment with SC144 significantly  
427 inhibited the activation of the gp130 receptor, thereby suppressing the downstream signaling cascade,  
428 including the phosphorylation of STAT3. Consistent with our mRNA observations, our protein analysis  
429 indicated a reduction in ABCA1 protein expression, while HMG-CoA expression was significantly  
430 increased, suggesting a potential shift toward cholesterol retention (**Figure 5F-5I**).

431 We then evaluated the functional significance of these changes through the use of a cholesterol efflux  
432 assay, and the results showed that SC144 treatment under oxLDL stimulation significantly increased  
433 cellular cholesterol levels by reducing its efflux to the media (**Figure 5J**). Intriguingly, we further  
434 examined the subcellular localization of cholesterol by staining with filipin to visualize cholesterol  
435 deposits (depicted in blue) and BODIPY 493/503 staining to visualize neutral lipids (depicted in green).  
436 Under conditions of gp130 inhibition, we observed an enhanced filipin signal, which partially colocalized  
437 with areas positive for neutral lipids (**Figure 5K**). While the semiquantitative nature of this staining  
438 necessitates further analyses to elucidate the dynamics of cholesterol and neutral lipids within the plasma  
439 membrane after gp130 inhibition, our observations suggest a notable accumulation of intracellular  
440 cholesterol in the treated group. In an attempted to translate this observation to a human *ex-vivo* model,  
441 we assessed the cholesterol efflux capacity of peripheral blood mononuclear cells (PBMCs) isolated from  
442 both lean and obese individuals. Furthermore, PBMCs obtained from lean subjects were pre-treated with  
443 SC-144, simulating the gp130 inhibitory milieu observed in obese participants. Fascinatingly, PBMCs  
444 from lean individuals exhibited superior cholesterol efflux capabilities compared to those from obese  
445 counterparts. Notably, upon gp130 inhibition, the cholesterol efflux potential of these cells was markedly  
446 attenuated, aligning closely with patterns observed in obese-derived PBMCs (**Figure 5L**). Collectively,  
447 our findings pertaining to gene and protein expression profiles underscore the involvement of cholesterol  
448 metabolism, particularly through pathways related to cholesterol synthesis and uptake, as influenced by  
449 gp130 inhibition. However, this increase in cholesterol synthesis is not matched by an equivalent increase  
450 in cholesterol clearance, as evidenced by the reduction in ABCA1 expression. These results shed light on  
451 the intricate interplay between gp130 signaling and macrophage cholesterol homeostasis.

452

453

454

## 455 **Discussion**

456 Obesity is characterized as a chronic inflammatory condition, and it is considered a major risk factor for  
457 the development of atherosclerosis. Under obesity setting, the elevation of several macrophage-induced  
458 chemokines and cytokines has been promoted as a key mediator of local and systemic inflammation,  
459 oxidative stress, and abnormal lipid metabolism within the arterial walls. Under these contacts, the role of  
460 IL-6 cytokine specifically in the development of atherosclerosis has long been debated, as its elevation in  
461 atherosclerotic patient plasma has been reported by several groups. Regardless, the direct impact of  
462 circulatory IL-6 on the progression of atherosclerosis remains not well defined. In this work, we aimed to  
463 characterize IL-6 cytokine secretion and IL-6R/gp130 receptor signaling in both lean and obese  
464 population and correlated our findings with atherosclerosis risk markers. Our findings provide compelling  
465 insights into the molecular intricacies of atherosclerosis, particularly the role of IL-6 receptors in  
466 modulating human macrophage cholesterol homeostasis. The marked decrease in IL-6 receptors  
467 expression on circulatory monocytes in obese individuals, specifically gp130 despite elevated IL-6  
468 secretion, suggests a complex regulatory mechanism that requires intensive further investigation. Similar  
469 to IL-6 secretion, the role of gp130 under inflammatory setting seemed to be diverse. In a study  
470 conducted by *Duan et al*, (21) it was demonstrated that CD146 interaction with gp130 and the subsequent  
471 activation of its signal is a major promoter of adipocyte infiltrated macrophages and a driven trigger for  
472 these macrophages to polarize toward a pro-inflammatory phenotype. However, this activation of pro-  
473 inflammatory response downstream of gp130 is also debated upon its protective outcome in part, by  
474 increasing the expression of suppressor of cytokine signalling-3 (SOCS3) (22, 23). Regardless, the role of  
475 gp130 expression seems to play a different role in metabolic diseases such as diabetes, obesity, and  
476 atherosclerosis. In a work presented by *Carbonaro et al*, it was shown that by restoring hepatic IL-6-  
477 gp130 signaling pathway through constitutive activation of gp130 substantially reduced lipid  
478 accumulation in human hepatocytes thus, preventing hepato-steatosis (24). This influence of gp130  
479 activation was further demonstrated to be a vital signal mediator in exercise induced weight reduction (25,  
480 26).

481 Indeed, in our mechanistical investigation, we observed an increase in intracellular lipid accumulation  
482 when macrophages were treated with gp130 inhibitor, as evidenced by increased cytoplasmic granularity  
483 and neutral lipid content, suggesting a direct impact of gp130 inhibition on lipid uptake and storage  
484 mechanisms. This is further corroborated by the upregulation of the PLIN2 gene, a marker of lipid droplet  
485 formation. To further identify the intricate of this lipid induction, we conducted a broad gene analysis of  
486 for different lipid processing genes. Even though all lipid uptake and shuttle genes showed significant  
487 upregulation under the stimulation of oxLDL, an interesting notable increase in LDLR expression under  
488 gp130 inhibition regardless of oxLDL supplementation hinted at a possible enhanced cholesterol uptake  
489 capacity. Moreover, similar observation was found in the expression of FABP5. Several studies have  
490 implicated both FABP4 and FABP5 in atherosclerotic lesions formation (27-29). However, it is very  
491 interesting to note that while FABP4 was only marginally detected in early and advanced lesions, the  
492 presence of FABP5 is found to be expressed abundantly in these lesions. This increase in expression of  
493 FABP5 is also found in areas mostly restricted to infiltrated foam cells (30). Furthermore, the association  
494 between FABP5 in particular and macrophage cholesterol efflux capacity (31) further supported the  
495 impact of gp130 inhibition on cholesterol regulation.



496 The absence of significant changes in ACACA expression, coupled with the observed reductions in  
497 FASN and DGAT gene expression, indicates a dampened *de novo* lipogenesis and triglyceride production  
498 under gp130 inhibition. This is consistent with a cellular attempt to limit further fatty acid synthesis in  
499 response to heightened lipid influx.

500 Another interesting observation we had was the influence of gp130 inhibition on downregulating genes  
501 involved in  $\beta$ -oxidation, such as ACADL and CPT1A/CPT2. In a recent work presented by *Zheng et al*, it  
502 was demonstrated that the influence of Atorvastatin; a statin medication used for the control of cholesterol  
503 levels, induced cardiac pleiotropic effects through inactivating p-STAT3, a transcription factor  
504 downstream of gp130 causing the inhibition of CPT1 signaling and thus inhibiting fatty acid oxidation  
505 (FAO) (32). Even though the authors believe that this effect holds a protective impact in preventing  
506 cardiac hypertrophy and dysfunction, it also further supports a state of altered lipid utilization and  
507 metabolism that is specifically tailored towards cholesterol homeostasis.

508 Paying more attention to the influence of gp130 on cholesterol homeostasis in the presence and absence  
509 of oxLDL supplementation, we conducted further characterization analysis of key genes involved in  
510 cholesterol *de novo* biosynthesis, storage, and exportation. The activation of the membrane-bound  
511 transcription factors SREBPs in both cholesterol synthesis as well as fatty acid synthesis has been well  
512 characterized, beside them being a driven factor for both cholesterol and fatty acid production, they also  
513 provide the mean by which cellular cholesterol exerts negative feedback on cholesterol synthesis (33,  
514 34). It is not surprising to observe a reduction in SREBF1 and SREBF2 gene expression under the  
515 stimulation of oxLDL when compared to vehicle control. However, the use of SC144 to inhibit gp130  
516 activity induced a sustained elevation in SREBF2 that was found not to be reduced under oxLDL  
517 stimulation. We believe that this sustains upregulation in SREBF2 subsequently aided the upregulation  
518 seen MVK gene expression consequently producing more HMG CoA reductase protein. Nonetheless, as  
519 we noticed this upregulation of cholesterol biosynthesis induced by the inhibition of gp130, we also  
520 observed strong inhibitory effect seen on ABCA1 at both its gene and protein levels. This observation  
521 suggests that under gp130 inhibition this observed intracellular lipid accumulation is more likely to be  
522 caused by cholesterol retention. Indeed, cholesterol immunofluorescence staining with Filipin III further  
523 defines this impact of cholesterol retention within gp130 inhibited cells. However, this impact was further  
524 defined when we investigated the mechanistic ability for THP-1 transformed macrophages to efflux  
525 cholesterol under oxLDL stimulation, we found that their ability was significantly abolished when treated  
526 with SC144 inhibitor. Translating these findings into a primary human model, we observed that the ability  
527 of lean individuals to probably efflux cholesterol from their macrophages indeed seems to be dependent  
528 on gp130 activation, as when we pre-treated lean individuals PBMCs with SC144 we observed  
529 significant reduction in these cells' ability to efflux cholesterol to a point where they became similar to  
530 obese individuals isolated cells and most likely due to similar impact identified in our THP-1 model.

531 In conclusion, the findings of this study shed light on the intricate dynamics of IL-6 receptors and their  
532 potential role in modulating human macrophage cholesterol homeostasis. By unraveling these molecular  
533 intricacies, this research lays the groundwork for future therapeutic interventions aimed at mitigating the  
534 progression of atherosclerosis and related cardiovascular diseases.

535

## 536 **Acknowledgements**

537 This work was supported by Kuwait Foundation for the Advancement of Sciences Grant RA CB-2023-  
538 017 (FAR.)



## 539 **Contributors**

540 FAR. conceived idea, acquired funds, designed study, conducted experiments, data curation, analyzed  
541 data, interpreted the results and wrote the manuscript. AAS. conducted experiments, data curation,  
542 analyzed data, interpreted the results, and participated in writing the original draft of the manuscript.  
543 NAM. participated in conducting experiments, data collection, data analysis, data interpretation and wrote  
544 original draft of the manuscript. FAM. participated in study designing, data interpretation, review &  
545 editing manuscript. RA. conceived idea, participated in study designing, interpreted the results, acquired  
546 funds, reviewed & editing manuscript. All authors contributed to reviewing the paper and all authors have  
547 read and approved the final version for submission.

## 548 **Data sharing statement**

549 Summarized data are available in the main text or the supplementary materials. There are no restrictions  
550 on material or data.

## 551 **Declaration of interests**

552 The authors have declared that no conflict of interest exists.

## 553 **Disclosure instructions**

554 During the preparation of this work the author(s) used QuillBot AI to improve readability and language.  
555 After using this QuillBot AI, the author(s) reviewed and edited the content as needed and take(s) full  
556 responsibility for the content of the publication.

557

558

## 559 **Figure legends.**

560 **Figure 1. IL-6 secretion is elevated in obese individuals' plasma and is associated with**  
561 **atherosclerosis related markers.** Plasma levels of atherosclerosis related cytokines secretion of (A) IL-  
562 6, (B) Total cholesterol, (C) TG, (D) CRP, and (E) HDL. Two-tailed /Wilcoxon–Mann–Whitney U tests  
563 were used to assess the differences between two Lean vs Obese. Pearson's/Spearman's correlation  
564 coefficient and linear regression analysis was conducted to investigate the relationship between secreted  
565 IL-6 cytokines and atherosclerosis related markers (F-I). All data are expressed as mean  $\pm$  SD.  $P \leq 0.05$   
566 was considered statistically significant (\*\* $P < 0.01$ , \*\*\*\* $P < 0.0001$ ).

567 **Figure 2: IL-6 receptors expression is markedly decreased in obese individuals' circulatory**  
568 **monocytes.** PBMCs were isolated from human blood samples obtained from lean and obese individuals.  
569 (A) Bar-graph of Flow cytometry analysis of CD14<sup>+</sup>CD126<sup>+</sup> subsets percentage, (B) Representative dot-  
570 plot analysis of CD14<sup>+</sup>CD126<sup>+</sup> subsets expression (B-J) Correlation between CD14<sup>+</sup>CD126<sup>+</sup> subset  
571 percentages and atherosclerosis related markers. Data are presented as mean  $\pm$  SD. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ ,  
572 \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

573 **Figure 3: IL-6 trans-membrane receptor gp130 is markedly decreased in obese individuals'**  
574 **circulatory monocytes.** PBMCs were isolated from human blood samples obtained from lean and obese  
575 individuals. (A) Bar-graph of Flow cytometry analysis of CD14<sup>+</sup>CD130<sup>+</sup> subsets percentage, (B)  
576 Representative dot-plot analysis of CD14<sup>+</sup>CD130<sup>+</sup> subsets expression (B-J) Correlation between

577 CD14<sup>+</sup>CD130<sup>+</sup> subset percentages and atherosclerosis related markers. Data are presented as mean  $\pm$  SD.  
578 \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

579 **Figure 4: Pharmaceutical inhibition of gp130 receptor induces lipid accumulation in macrophage**  
580 **transformed THP-1 cells.** THP-1-derived macrophages were pre-treated with gp130 inhibitor or vehicle  
581 control followed by stimulation with OxLDL (150uM; Thermo # L34357). (A) Representative dot plot of  
582 cellular granulation of macrophages with representative image of Oil red O staining. (B) Smi -  
583 quantitative analysis of Oil red O extraction. (C) Gene expression analysis of PLIN2. (D) Gene  
584 expression of LDLR. (E) Gene expression of CD36. (F) Gene expression of FABP4. (G) Gene expression  
585 of FABP5. (H) Gene expression of ACACA. (I) Gene expression of FASN. (J) Gene Expression of  
586 DGAT. (K) Gene Expression of ACADL. (L) Gene expression of CPT1A and (M) Gene expression of  
587 CPT2. Data are presented as mean  $\pm$  SEM values (n=3-4) and compared between groups using one-way  
588 ANOVA with Tukey's multiple comparisons test. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

589 **Figure 5: Pharmaceutical inhibition of gp130 receptor modulates cholesterol homeostasis in**  
590 **macrophage transformed THP-1 cells.** THP-1-derived macrophages were pre-treated with gp130  
591 inhibitor or vehicle control followed by stimulation with OxLDL (150uM; Thermo # L34357). QRT-PCR  
592 analysis was conducted for (A) SREBP1 gene expression. (B) SREBP2 gene expression. (C) MVK gene  
593 expression. (D) ABCA1 gene expression. (E) ABCG1 gene expression. Western Blot analysis for protein  
594 expression for (F) phospho-STAT3 corrected over  $\beta$ -actin. (G) ABCA1 corrected over  $\beta$ -actin. (H) HMG-  
595 COA corrected over  $\beta$ -actin. (I) Representative immune blots for protein expression. (J) Cholesterol  
596 efflux assay conducted for THP-1 transformed macrophages treated with SC144. (K) Immun-florescence  
597 microscopy images of treated THP-1 transformed macrophages stained with filipin III cholesterol stain  
598 (Blue), BODIPY 493/503 for neutral lipids (Green) and Phalloidin to labeled actin filaments (red) (Scale  
599 Bar 5 $\mu$ M). (L) Cholesterol efflux assay conducted on isolated and treated PBMC from both Lean and  
600 Obese individuals. Data are presented as mean  $\pm$  SEM values (n=3-4) and compared between groups  
601 using one-way ANOVA with Tukey's multiple comparisons test. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ ,  
602 \*\*\*\* $p \leq 0.0001$ .

603

604

605

606

## 607 **References**

- 608 1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global,  
609 regional, and national comparative risk assessment of 79 behavioural, environmental and occupational,  
610 and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global  
611 Burden of Disease Study 2013. *Lancet*. 2015;386(10010):2287-323.
- 612 2. Jiang H, Zhou Y, Nabavi SM, Sahebkar A, Little PJ, Xu S, et al. Mechanisms of Oxidized LDL-  
613 Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. *Front*  
614 *Cardiovasc Med*. 2022;9:925923.
- 615 3. Lee-Rueckert M, Lappalainen J, Kovanen PT, Escola-Gil JC. Lipid-Laden Macrophages and  
616 Inflammation in Atherosclerosis. *Front Cardiovasc Med*. 2022;9:777822.

- 617 4. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger  
618 receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low  
619 density lipoprotein leading to lipid loading in macrophages. *J Biol Chem.* 2002;277(51):49982-8.
- 620 5. von Eckardstein A. LDL Contributes to Reverse Cholesterol Transport. *Circ Res.* 2020;127(6):793-  
621 5.
- 622 6. Kojima Y, Weissman IL, Leeper NJ. The Role of Efferocytosis in Atherosclerosis. *Circulation.*  
623 2017;135(5):476-89.
- 624 7. Kumar R, Chhillar N, Gupta DS, Kaur G, Singhal S, Chauhan T. Cholesterol homeostasis,  
625 mechanisms of molecular pathways, and cardiac health: a current outlook. *Curr Probl Cardiol.*  
626 2023;102081.
- 627 8. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological  
628 implications. *J Clin Invest.* 2002;110(7):905-11.
- 629 9. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular  
630 Disease. *Circ Res.* 2021;128(11):1728-46.
- 631 10. Nakashima K, Taga T. gp130 and the IL-6 family of cytokines: signaling mechanisms and  
632 thrombopoietic activities. *Semin Hematol.* 1998;35(3):210-21.
- 633 11. Wainstein MV, Mossmann M, Araujo GN, Gonçalves SC, Gravina GL, Sangalli M, et al. Elevated  
634 serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients  
635 referred for coronary angiography. *Diabetol Metab Syndr.* 2017;9:67.
- 636 12. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the  
637 risk of future myocardial infarction among apparently healthy men. *Circulation.* 2000;101(15):1767-72.
- 638 13. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, et al. Involvement of interleukin-6 in  
639 atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein  
640 E-deficient mice. *Atherosclerosis.* 2001;156(2):315-20.
- 641 14. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, et al. Impact of interleukin-6  
642 on plaque development and morphology in experimental atherosclerosis. *Circulation.*  
643 2004;110(22):3493-500.
- 644 15. Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, et al. Interleukin-6 protects  
645 human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory  
646 response. *J Biol Chem.* 2011;286(35):30926-36.
- 647 16. Bahman F, AlSaeed H, Albeloushi S, Al-Mulla F, Ahmad R, Al-Rashed F. The role of TLR2 in  
648 exercise-induced immunomodulation in normal weight individuals. *Sci Rep.* 2023;13(1):10703.
- 649 17. Al-Rashed F, Sindhu S, Al Madhoun A, Ahmad Z, AlMekhled D, Azim R, et al. Elevated resting  
650 heart rate as a predictor of inflammation and cardiovascular risk in healthy obese individuals. *Sci Rep.*  
651 2021;11(1):13883.
- 652 18. Haider MJA, Albaqsumi Z, Al-Mulla F, Ahmad R, Al-Rashed F. SOCS3 Regulates Dectin-2-Induced  
653 Inflammation in PBMCs of Diabetic Patients. *Cells.* 2022;11(17).
- 654 19. Al-Rashed F, Alghaith A, Azim R, AlMekhled D, Thomas R, Sindhu S, et al. Increasing the Duration  
655 of Light Physical Activity Ameliorates Insulin Resistance Syndrome in Metabolically Healthy Obese  
656 Adults. *Cells.* 2020;9(5).
- 657 20. Zegeye MM, Lindkvist M, Fälker K, Kumawat AK, Paramel G, Grenegård M, et al. Activation of  
658 the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory  
659 response in human vascular endothelial cells. *Cell Commun Signal.* 2018;16(1):55.
- 660 21. Duan H, Jing L, Xiang J, Ju C, Wu Z, Liu J, et al. CD146 Associates with Gp130 to Control a  
661 Macrophage Pro-inflammatory Program That Regulates the Metabolic Response to Obesity. *Adv Sci*  
662 (Weinh). 2022;9(13):e2103719.

- 663 22. Men L, Guo J, Cao Y, Huang B, Wang Q, Huo S, et al. IL-6/gp130/STAT3 signaling contributed to  
664 the activation of the PERK arm of the unfolded protein response in response to chronic  $\beta$ -adrenergic  
665 stimulation. *Free Radic Biol Med*. 2023;205:163-74.
- 666 23. Martino N, Bossardi Ramos R, Chuy D, Tomaszek L, Adam AP. SOCS3 limits TNF and endotoxin-  
667 induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human  
668 endothelial cells. *Am J Physiol Cell Physiol*. 2022;323(2):C556-C69.
- 669 24. Carbonaro M, Wang K, Huang H, Frleta D, Patel A, Pennington A, et al. IL-6-GP130 signaling  
670 protects human hepatocytes against lipid droplet accumulation in humanized liver models. *Sci Adv*.  
671 2023;9(15):eadf4490.
- 672 25. Odermatt TS, Dedual MA, Borsigova M, Wueest S, Konrad D. Adipocyte-specific gp130 signalling  
673 mediates exercise-induced weight reduction. *Int J Obes (Lond)*. 2020;44(3):707-14.
- 674 26. Minafra AR, Chadt A, Rafii P, Al-Hasani H, Behnke K, Scheller J. Interleukin 6 receptor is not  
675 directly involved in regulation of body weight in diet-induced obesity with and without physical exercise.  
676 *Front Endocrinol (Lausanne)*. 2022;13:1028808.
- 677 27. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, et al. Adipocyte/macrophage fatty  
678 acid binding proteins control integrated metabolic responses in obesity and diabetes. *Cell Metab*.  
679 2005;1(2):107-19.
- 680 28. Syamsunarno MR, Iso T, Yamaguchi A, Hanaoka H, Putri M, Obokata M, et al. Fatty acid binding  
681 protein 4 and 5 play a crucial role in thermogenesis under the conditions of fasting and cold stress. *PLoS*  
682 *One*. 2014;9(6):e90825.
- 683 29. Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of  
684 diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. *Nature*. 2007;447(7147):959-  
685 65.
- 686 30. Umbarawan Y, Enoura A, Ogura H, Sato T, Horikawa M, Ishii T, et al. FABP5 Is a Sensitive Marker  
687 for Lipid-Rich Macrophages in the Luminal Side of Atherosclerotic Lesions. *Int Heart J*. 2021;62(3):666-  
688 76.
- 689 31. Furuhashi M, Ogura M, Matsumoto M, Yuda S, Muranaka A, Kawamukai M, et al. Serum FABP5  
690 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux  
691 from macrophages. *Sci Rep*. 2017;7(1):217.
- 692 32. Zheng P, Wu H, Gu Y, Li L, Hu R, Ma W, et al. Atorvastatin ameliorates lipid overload-induced  
693 mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through  
694 inactivation of the p-STAT3/CPT1 pathway. *Biomed Pharmacother*. 2023;157:114024.
- 695 33. Shi Q, Chen J, Zou X, Tang X. Intracellular Cholesterol Synthesis and Transport. *Front Cell Dev*  
696 *Biol*. 2022;10:819281.
- 697 34. Tibbo AJ, Hartley A, Vasan R, Shaw R, Galbraith L, Mui E, et al. MBTPS2 acts as a regulator of  
698 lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer. *Br J Cancer*.  
699 2023;128(11):1991-9.
- 700 35. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring*  
701 *Harb Perspect Biol*. 2014;6(10):a016295.

702

703


704

705

706

707  
708  
709  
710  
711  
712  
713

Figure 1



714  
715  
716  
717

Figure 1. IL-6 secretion is elevated in obese individuals' plasma and is associated with markers linked to atherosclerosis. IL-6 was determined in the plasma samples of lean and obese individuals using ELISA(A). Markers linked to atherosclerosis were determined. (B) Total cholesterol, (C) TG, (D) CRP, and (E) HDL. Two-tailed /Wilcoxon–Mann–Whitney U tests were

718 used to assess the differences between Lean vs Obese. Pearson's/Spearman's correlation coefficient and linear regression analysis  
719 was conducted to investigate the relationship between secreted IL-6 cytokine and atherosclerosis related markers (F-I). All data  
720 are expressed as mean  $\pm$  SD.  $P \leq 0.05$  was considered statistically significant (\*\* $P < 0.01$ , \*\*\*\* $P < 0.0001$ ).


721

722

723

724

725 **Figure 2**



726

727 **Figure 2: IL-6 receptors expression is markedly decreased in obese individuals' circulatory monocytes.** PBMCs  
728 were isolated from human blood samples obtained from lean and obese individuals. (A) Bar-graph of Flow cytometry analysis of  
729 CD14<sup>+</sup>CD126<sup>+</sup> subset percentages, (B) Representative dot-plot analysis of CD14<sup>+</sup>CD126<sup>+</sup> subsets expression. (B-J) Correlation



730 between CD14<sup>+</sup>CD126<sup>+</sup> subset percentages and atherosclerosis related markers. Data are presented as mean ± SD. \*p≤0.05,  
731 \*\*p≤0.01, \*\*\*p≤0.001, \*\*\*\*p≤0.0001.

732


733

734

735

736

737 **Figure 3**




738

739 **Figure 3: IL-6 trans-membrane receptor gp130 is markedly decreased in obese individuals' circulatory**  
 740 **monocytes.** PBMCs were isolated from human blood samples obtained from lean and obese individuals. (A) Bar-graph of Flow  
 741 cytometry analysis of CD14<sup>+</sup>CD130<sup>+</sup> subset percentages, (B) Representative dot-plot analysis of CD14<sup>+</sup>CD130<sup>+</sup> subset  
 742 expression (B-J) Correlation between CD14<sup>+</sup>CD130<sup>+</sup> subset percentages and atherosclerosis related markers. Data are presented  
 743 as mean ± SD. \*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001, \*\*\*\*p≤0.0001.

744

745

746




747 **Figure 4**

748

749 **Figure 4: Pharmaceutical inhibition of gp130 receptor induces lipid accumulation in macrophages derived from**  
 750 **THP-1 cells.** Macrophages were pre-treated with gp130 inhibitor or vehicle control followed by stimulation with OxLDL  
 751 (150uM; Thermo # L34357). (A) Representative dot plot of cellular granulation of macrophages with representative image of Oil  
 752 red O staining. (B) Smi - quantitative analysis of Oil red O extraction. (C) Gene expression analysis of PLIN2. (D) Gene  
 753 expression of LDLR. (E) Gene expression of CD36. (F) Gene expression of FABP4. (G) Gene expression of FABP5. (H) Gene  
 754 expression of ACACA. (I) Gene expression of FASN. (J) Gene Expression of DGAT. (K) Gene Expression of ACADL. (L) Gene  
 755 expression of CPT1A and (M) Gene expression of CPT2. Data are presented as mean  $\pm$  SEM values (n=3-4) and compared

756 between groups using one-way ANOVA with Tukey's multiple comparisons test. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ ,  
 757 \*\*\*\* $p \leq 0.0001$ .

758 **Figure 5**



759 **Figure 5: Pharmaceutical inhibition of gp130 receptor modulates cholesterol homeostasis in macrophage**  
 760 **transformed THP-1 cells.** THP-1-derived macrophages were pre-treated with gp130 inhibitor or vehicle control followed by  
 761 stimulation with OxLDL (150uM; Thermo # L34357). QRT-PCR analysis was conducted for (A) SREBP1 gene expression. (B)  
 762 SREBP2 gene expression. (C) MVK gene expression. (D) ABCA1 gene expression. (E) ABCG1 gene expression. Western Blot  
 763 analysis for protein expression for (F) phospho-STAT3 corrected over  $\beta$ -actin. (G) ABCA1 corrected over  $\beta$ -actin. (H) HMG-

764 COA corrected over  $\beta$ -actin. (I) Representative immune blots for protein expression. (J) Cholesterol efflux assay conducted for  
765 THP-1 transformed macrophages treated with SC144. (K) Immun-floresence microscopy images of treated THP-1 transformed  
766 macrophages stained with filipin III cholesterol stain (Blue), BODIPY 493/503 for neutral lipids (Green) and Phalloidin to  
767 labeled actin filaments (red) (Scale Bar 5 $\mu$ M). (L) Cholesterol efflux assay conducted on isolated and treated PBMC from both  
768 Lean and Obese individuals. Data are presented as mean  $\pm$  SEM values (n=3-4) and compared between groups using one-way  
769 ANOVA with Tukey's multiple comparisons test. \*p $\leq$ 0.05, \*\*p $\leq$ 0.01, \*\*\*p $\leq$ 0.001, \*\*\*\*p $\leq$ 0.0001.

770